Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next‐Generation Sequencing in Detecting Actionable Driver Mutations in Anti‐EGFR Naive Metastatic Colorectal Cancer

BACKGROUND: Direct comparisons between Guardant360 (G360) circulating tumor DNA (ctDNA) and FoundationOne (F1) tumor biopsy genomic profiling in metastatic colorectal cancer (mCRC) are limited. We aim to assess the concordance across overlapping genes tested in both F1 and G360 in patients with mCRC...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Gupta, Rohan, Othman, Tamer, Chen, Chen, Sandhu, Jaideep, Ouyang, Ching, Fakih, Marwan
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Gastrointestinal Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066697/
https://ncbi.nlm.nih.gov/pubmed/32162812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0441
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki